Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 755 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Renal Disease Clear all
Completed Not applicable Interventional Results available

Outlook Quality of Life Intervention Study

NCT01044290
View directory record Official record
Conditions
Cancer, Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), End Stage Renal Disease (ESRD)
Interventions
Life Completion, Attention Control
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 95 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

NCT01074125
View directory record Official record
Conditions
Hyperphosphatemia, End-Stage Renal Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
15
States / cities
Westminster, Colorado • Pembroke Pines, Florida • Augusta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

NCT01628120
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
115
States / cities
Azusa, California • Bakersfield, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Not applicable Interventional

Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

NCT00004285
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Standard dose, low flux hemodialysis, Standard dose, high flux hemodialysis, High dose, low flux hemodialysis, High dose, high flux hemodialysis
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 1, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

NCT06190717
View directory record Official record
Conditions
Diabetes, End Stage Renal Disease
Interventions
EchoMark/EchoSure, Standard of Care
Device · Procedure
Lead sponsor
Sonavex, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 1, 2026, 2:28 PM EDT
Completed No phase listed Observational

Fluid Status of ESRD Patients Undergoing Dialysis

NCT07217470
View directory record Official record
Conditions
ESRD (End Stage Renal Disease)
Interventions
Not listed
Lead sponsor
HemoCept Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Not applicable Interventional

House Calls and Peer Mentorship

NCT03354910
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
House Call, Peer Mentorship
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598442
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 1, 2026, 2:28 PM EDT
Completed No phase listed Observational

Fluid Status of Dialysis Subjects

NCT07217041
View directory record Official record
Conditions
ESRD (End Stage Renal Disease)
Interventions
Not listed
Lead sponsor
HemoCept Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 1, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional

Deceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage

NCT07385651
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Chronic Kidney Disease (Stages 4 and 5), Kidney Transplantation Recipients
Interventions
10˚C deceased donor kidney storage using Traferox XPort
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Not applicable Interventional

Volume,Sodium and Blood Pressure Management in HD

NCT01766882
View directory record Official record
Conditions
End Stage Renal Failure
Interventions
Lower sodium intervention, Progressive Challenge to Post Dialysis Weight
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 1, 2026, 2:28 PM EDT
Not listed Phase 3 Interventional

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

NCT00628680
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
AAT-023 solution (Zuragen), Heparin
Device · Drug
Lead sponsor
Ash Access Technology
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
22
States / cities
Bakersfield, California • Lynwood, California • Middlebury, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473420
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease
Interventions
Epoetin Hospira, Epogen Amgen
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
73
States / cities
Azusa, California • Bakersfield, California • Long Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 1, 2026, 2:28 PM EDT
Terminated Not applicable Interventional

The Effect of Oxygen on Healing an Artery From the "Injury" of Surgery

NCT00863603
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
oxygen
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 4 Interventional Results available

How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis

NCT00528788
View directory record Official record
Conditions
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Interventions
doxercalciferol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597753
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin Alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
89
States / cities
Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

NCT01715259
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Abiraterone acetate: participants with end-stage renal disease, Abiraterone acetate: matched control participants with normal renal function
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Helping Olfaction and Nutrition On Renal Replacement

NCT02479451
View directory record Official record
Conditions
End Stage Renal Disease, Olfactory Disorders
Interventions
Theophylline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Not applicable Interventional Results available

Treatment Modification to Reduce Symptom Burden in Hemodialysis

NCT01775800
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Treatment modification
Other
Lead sponsor
The Rogosin Institute
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Nefecon, Placebo oral capsule
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 1 Interventional

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

NCT02145325
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expanded Tregs
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Journeys to Wellness: A Transplant Candidate Study

NCT01254214
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
tMBSR, Support group
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 1, 2026, 2:28 PM EDT
Completed No phase listed Observational

A Study Evaluating the Association of Inflammation With Hemodialysis Access Type

NCT01011985
View directory record Official record
Conditions
End Stage Renal Disease, Inflammation
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 1, 2026, 2:28 PM EDT
Completed Phase 1 Interventional

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

NCT01978587
View directory record Official record
Conditions
Anemia in Chronic Kidney Disease
Interventions
JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 1, 2026, 2:28 PM EDT